

Kidney Cancer: New Treatments Bring New Hope

How to Receive CE Credit

To earn free CE credit for watching this program, you must complete this test online.

Go to www.discoveryhealthCME.com and follow the instructions to complete the post-test and evaluation online. You must be registered and signed-in in order to take the test online. Upon successful completion of the test and the evaluation, you will be asked to select your professional category and you will be able to print the appropriate credit certificate right from your computer. You must answer a minimum of 8 out of 10 questions correctly in order to earn CE credit.

CE Test Questions

1. Which of the following statements about kidney cancer is correct?
 - a. Kidney cancer accounts for about 8% of all adult cancer cases.
 - b. The median age of diagnosis for kidney cancer is 65.
 - c. Kidney cancer is more common among women than men.
 - d. There are about 50,000 deaths from kidney cancer annually.

2. The elements of initial imaging for all patients with kidney cancer should include:
 - a. Abdominal/pelvic CT or MRI and chest imaging
 - b. Abdominal/pelvic CT or MRI and bone scan
 - c. Abdominal/pelvic CT or MRI, chest imaging, and brain MRI
 - d. Abdominal/pelvic CT or MRI, bone scan, and brain MRI

3. In appropriately selected patients, the advantages of partial nephrectomy over radical nephrectomy include:
 - a. A simpler surgical procedure, when done laparoscopically.
 - b. Better oncologic outcomes than radical nephrectomy.
 - c. The retention of part of the kidney, which may allow for wider options in terms of future treatment.
 - d. Partial nephrectomy is not recommended in the setting of kidney cancer.

4. Laparoscopic radical nephrectomy:
 - a. Appears to have better oncologic outcomes, when compared to open surgery.
 - b. Appears to have oncologic outcomes similar to those of open surgery, in appropriately selected patients.
 - c. Is preferable to open surgery in nearly every case.
 - d. Should not be used.

5. The use of adjuvant therapy in the setting of localized kidney cancer:
 - a. Is recommended for most patients following surgery.
 - b. Has been proven to improve prognosis when interferon is used.
 - c. Is appropriate for selected patients in the setting of a clinical trial.
 - d. Is never appropriate, as it has been shown to worsen outcomes.

6. According to current NCCN guidelines, three options have Category 1 evidence for first-line pharmacotherapy of kidney cancer with predominant clear cell histology. Category 1 means that there is uniform NCCN consensus, based on high-level evidence, that the recommendation is appropriate. These three options are:
 - a. Sunitinib, temsirolimus (for poor-prognosis patients), and bevacizumab plus interferon
 - b. Sorafenib, sunitinib, and temsirolimus (for poor-prognosis patients)
 - c. Sunitinib, interleukin-2, and bevacizumab plus interferon
 - d. Sunitinib, temsirolimus (for poor-prognosis patients), and interleukin-2

7. The current targeted therapies for kidney cancer are understood to act by mechanisms including which of the following?
 - a. Inhibition of angiogenesis
 - b. Enhancement of immune response
 - c. Interruption of DNA replication
 - d. All of the above

8. A patient's prognosis should be considered when choosing a treatment for kidney cancer. One way to stratify patients is to use criteria established by researchers at the Memorial Sloan Kettering Cancer Center. These criteria include:
 - a. LDH level, calcium level, white blood cell count, and degree of anemia
 - b. Calcium level, white blood cell count, performance status, and timing of disease progression
 - c. Presence of anemia, LDH level, calcium level, performance status, and timing of disease progression
 - d. Degree of anemia, LDH level, calcium level, and performance status

9. Side effects of current targeted therapies for kidney cancer include:
 - a. Decline in cardiac function with sunitinib
 - b. Hand-foot syndrome with sunitinib
 - c. Hyperlipidemia with temsirolimus
 - d. Pulmonary fibrosis with temsirolimus
 - e. a and c only
 - f. All of the above

10. Current NCCN guidelines include enrollment in a clinical trial as a preferred option for patients with predominantly clear cell histology, when disease has progressed after first-line pharmacotherapy. One reason for this recommendation is:
- a. None of the current options for treatment has proven to be effective in this setting.
 - b. More information is needed about how options for targeted therapy can best be used in this setting.
 - c. More information is needed about how immunotherapy can best be used in this setting.
 - d. b and c only
 - e. All of the above

CE Evaluation

Kidney Cancer: New Treatments Bring New Hope

1) The program content helped me to achieve the following objectives:

Choose the appropriate imaging studies for the staging of kidney cancer

Strongly Agree Agree Undecided Disagree Strongly Disagree

Describe surgical techniques utilized in the management of kidney cancer

Strongly Agree Agree Undecided Disagree Strongly Disagree

Summarize the use of targeted agents for unresectable and recurrent kidney cancer

Strongly Agree Agree Undecided Disagree Strongly Disagree

2) Time spent completing this activity?

< 30 min 30 min 45 min 1 hr 1.5 hrs >1.5 hrs

Rate the extent to which you agree or disagree:

3) You were satisfied with the overall quality of this activity.

Strongly Agree Agree Undecided Disagree Strongly Disagree

4) Participation in this activity changed your knowledge/attitudes.

Strongly Agree Agree Undecided Disagree Strongly Disagree

5) You will make a change in your practice as a result of participation in this activity.

Strongly Agree Agree Undecided Disagree Strongly Disagree

6) The activity presented scientifically rigorous, unbiased, and balanced information.

Strongly Agree Agree Undecided Disagree Strongly Disagree

7) Individual presentations were free of commercial bias.

Strongly Agree Agree Undecided Disagree Strongly Disagree

8) The program was up-to-date in terms of current practices and issues.

Strongly Agree Agree Undecided Disagree Strongly Disagree

9) Which ONE of the following best describes the impact of this activity on you:

a) I plan to incorporate these updates in cancer management into my practice.

b) I do not plan to incorporate these updates in cancer management into my practice.

10) For Question #9, if you selected "B" please list any factors that may be acting as barriers to implementing change.

11) If commercial bias was noted, please explain.

12) On what topic(s) would you like to receive future education?

13) Are you interested in participating in future Discovery Health CME programs?

- Not at all Somewhat Very Extremely

14) Additional Feedback.

15) Please tell us how you found out about Discovery Health CME.

- Direct Mail Invitation
 Journal of the National Comprehensive Cancer Network Ad
 Email Invitation
 Television Commercial
 Journal of Clinical Oncology Ad
 New England Journal of Medicine Ad
 Internet Search Engine
 American Journal of Clinical Oncology Ad
 Oncology Times Ad
 HemOnc Today Ad
 Clinical Advances in Hematology & Oncology Ad
 The Oncologist Ad
 Other (please indicate): _____